Samlet referenceliste

(1)   Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic Primary Hyperparathyroidism: Further Characterization of a New Clinical Phenotype. Journal of Clinical Endocrinology Metabolism. 2007;92:3001-5.

(2)   Rejnmark L, Amstrup AK, Mollerup CL, Heickendorff L, Mosekilde L. Further Insights into the Pathogenesis of Primary Hyperparathyroidism: A Nested Case-Control Study. Journal of Clinical Endocrinology & Metabolism. 2012.

(3)   Carlson D. Parathyroid Pathology: Hyperparathyroidism and Parathyroid Tumors. Archives of Pathology & Laboratory Medicine. 2010;134:1639-44.

(4)   Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 1997;51:328-36.

(5)   Farnebo F, Höög A, Sandelin K, Larsson C, Farnebo LO. Decreased expression of calcium-sensing receptor messenger ribonucleic acids in parathyroid adenomas. Surgery. 1998;124:1094-99.

(6)   Diaz A, Danon M, Crawford J. McCune-Albright syndrome and disorders due to activating mutations of GNAS1. J Pediatr Endocrinol Metab. 2007;20:853-80.

(7)   Kassem M, Kruse TA, Wong FK, Larsson C, Teh BT. Familial isolated hyperparathyroidism as a variant of multiple endocrine neoplasia type 1 in a large Danish pedigree. J Clin Endocrinol Metab. 2000;85:165-67.

(8)   Vestergaard P. [Multiple endocrine neoplasia type 2a and 2b]. Ugeskr Laeger. 1996;158:590-593.

(9)   Iacobone M, Barzon L, Porzionato A, Masi G, Macchi V, Marino F et al. Parafibromin expression, single-gland involvement, and limited parathyroidectomy in familial isolated hyperparathyroidism. Surgery. 2007;142:984-91.

(10)   Newey PJ, Bowl MR, Cranston T, Thakker RV. Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Hum Mutat. 2010;31:295-307.

(11)   Abdelgadir Adam M, Untch BR, Olson JA. Parathyroid Carcinoma: Current Understanding and New Insights into Gene Expression and Intraoperative Parathyroid Hormone Kinetics. Oncologist. 2010;15:61-72.

(12)   Masi G, Barzon L, Iacobone M, Viel G, Porzionato A, Macchi V et al. Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism. Endocrine-Related Cancer. 2008;15:1115-26.

(13)   Sharretts JM, Kebebew E, Simonds WF. Parathyroid Cancer. Seminars in Oncology. 2010;37:580-590.

(14)   Vestergaard P, Mosekilde L. Incidens af primær hyperparatyroidisme, hyppighed af operation og mortalitet belyst ved data fra Landspatientregistret. Ugeskr Laeger. 2004;166:41-45.

(15)   Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg. 2003;27:216-22.

(16)   Jorde R, Bønaa KH, Sundsfjord J. Primary hyperparathyroidism detected in a health screening: The Tromsø Study. Journal of Clinical Epidemiology. 2000;53:1164-69.

(17)   Siilin H, Rastad J, Ljunggren Ö, Lundgren E. Disturbances of Calcium Homeostasis Consistent with Mild Primary Hyperparathyroidism in Premenopausal Women and Associated Morbidity. Journal of Clinical Endocrinology & Metabolism. 2008;93:47-53.

(18)   Bolland MJ, Grey AB, Orr-Walker BJ, Horne AM, Evans MC, Clearwater JM et al. Prospective 10-year study of postmenopausal women with asymptomatic primary hyperparathyroidism. N Z Med J. 2008;121:18-29.

(19)   Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E et al. The Natural History of Primary Hyperparathyroidism with or without Parathyroid Surgery after 15 Years. Journal of Clinical Endocrinology Metabolism. 2008;93:3462-70.

(20)   Bollerslev J, Marcocci C, Sosa M, Nordenstrøm J, Bouillon R, Mosekilde L. Evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. Eur J Endocrinol. 2011.

(21)   Almquist M, Bergenfelz A, Måtensson H, Thier M, Nordenstrøm E. Changing biochemical presentation of primary hyperparathyroidism. Langenbeck’s Archives of Surgery. 2010;395:925-28.

(22)   Chan AK, Duh QY, Katz MH, Siperstein AE, Clark OH. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy. A case-control study. Ann Surg. 1995;222:402-12.

(23)   Eastell R, Arnold A, Brandi ML, Brown EM, D’Amour P, Hanley DA et al. Diagnosis of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop. J Clin Endocrinol Metab. 2009;94:340-350.

(24)   Souberbielle JC, Cormier C, Kindermans C, Gao P, Cantor T, Forette F et al. Vitamin D Status and Redefining Serum Parathyroid Hormone Reference Range in the Elderly. J Clin Endocrinol Metab. 2001;86:3086-90.

(25)   Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L. Determinants of plasma PTH and their implication for defining a reference interval. Clin Endocrinol (Oxf). 2011;74:37-43.

(26)   Parks JH, Coe FL, Evan AP, Worcester EM. Clinical and laboratory characteristics of calcium stone-formers with and without primary hyperparathyroidism. BJU International. 2009;103:670-678.

(27)   Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clinical Endocrinology. 2005;63:506-13.

(28)   Silverberg SJ. Vitamin D deficiency and primary hyperparathyroidism. J Bone Miner Res. 2007;22 Suppl 2:V100-V104.

(29)   Farahnak P, Lärfars G, Sten-Linder M, Nilsson IL. Mild Primary Hyperparathyroidism: Vitamin D Deficiency and Cardiovascular Risk Markers. Journal of Clinical Endocrinology & Metabolism. 2011;96:2112-18.

(30)   Rolighed L, Bollerslev J, Mosekilde L. Vitamin D treatment in primary hyperparathyroidism. Curr Drug Saf. 2011;6:100-107.

(31)   Moosgaard B, Vestergaard P, Heickendorff L, Mosekilde L. Plasma 1,25-dihydroxyvitamin-D levels in primary hyperparathyroidism depend on sex, body mass index, plasma phosphate and renal function. Clinical Endocrinology. 2007;66:35-42.

(32)   Bolland MJ, Grey AB, Gamble GD, Reid IR. Association between Primary Hyperparathyroidism and Increased Body Weight: A Meta-Analysis. Journal of Clinical Endocrinology Metabolism. 2005;90:1525-30.

(33)   Lundgren E, Ljunghall S, Akerstrom G, Hetta J, Mallmin H, Rastad J. Case-control study on symptoms and signs of “asymptomatic” primary hyperparathyroidism. Surgery. 1998;124:980-985.

(34)   Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-Year Prospective Study of Primary Hyperparathyroidism with or without Parathyroid Surgery. N Engl J Med. 1999;341:1249-55.

(35)   Rejnmark L, Abrahamsen B, Ejersted C, Hyldstrup L, Jensen JEB, Madsen OR et al. Vejledning til udredning og behandling af osteoporose. 1 ed. Dansk Knoglemedicinsk Selskab (www.dkms.dk); 2009.

(36)   Vignali E, Viccica G, Diacinti D, Cetani F, Cianferotti L, Ambrogini E et al. Morphometric Vertebral Fractures in Postmenopausal Women with Primary Hyperparathyroidism. Journal of Clinical Endocrinology & Metabolism. 2009;94:2306-12.

(37)   Moosgaard B, Christensen SE, Vestergaard P, Heickendorff L, Christiansen P, Mosekilde L. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2008;68:707-15.

(38) Cummings SR, Kelsey JL, Nevitt MC, O’Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev. 1985;7:178-208.

(39)   Rejnmark L, Vestergaard P, Mosekilde L. Nephrolithiasis and Renal Calcifications in Primary Hyperparathyroidism. Journal of Clinical Endocrinology & Metabolism. 2011.

(40)   Miller NL, Lingeman JE. Management of kidney stones. BMJ. 2007;334:468-72.

(41)   Vieweg J, Teh C, Freed K, Leder RA, Smith RH, Nelson RH et al. Unenhanced helical computerized tomography for the evaluation of patients with acute flank pain. J Urol. 1998;160:679-84.

(42)   Hamm M, Knöpfle E, Wartenberg S, Wawroschek F, Weckermann D, Harzmann R. Low Dose Unenhanced Helical Computerized Tomography For The Evaluation Of Acute Flank Pain. The Journal of Urology. 2002;167:1687-91.

(43)   Hindié E, Ugur Ö, Fuster D, O’Doherty MJ, Grassetto G, Ureña P et al. 2009 EANM parathyroid guidelines. European Journal of Nuclear Medicine and Molecular Imaging. 2009;36:1201-16.

(44)   Rasmussen K, Larsen LP, Arveschoug A, Theil NJ, Vestergaard P, Ronning H et al. Predictive value of parathyroid scintigraphy in the preoperative evaluation of patients with primary hyperparathyroidism. Scand J Surg. 2006;95:199-204.

(45)   Eslamy HK, Ziessman HA. Parathyroid scintigraphy in patients with primary hyperparathyroidism: 99mTc sestamibi SPECT and SPECT/CT. Radiographics. 2008;28:1461-76.

(46)   Ahuja AT, Wong KT, Ching ASC, Fung MK, Lau JYW, Yuen EHY et al. Imaging for primary hyperparathyroidism – what beginners should know. Clinical Radiology. 2004;59:967-76.

(47)   Otto D, Boerner AR, Hofmann M, Brunkhorst T, Meyer GJ, Petrich T et al. Pre-operative localisation of hyperfunctional parathyroid tissue with 11C-methionine PET  . European Journal of Nuclear Medicine and Molecular Imaging. 2004;31:1405-12.

(48)   Tang BN-T, Moreno-Reyes R, Blocklet D, Corvilain B, Cappello M, Delpierre I et al. Accurate pre-operative localization of pathological parathyroid glands using 11C-methionine PET/CT. Contrast Media Mol Imaging. 2008;3:157-63.

(49)   Rubello D, Fanti S, Nanni C, Farsad M, Castellucci P, Boschi S et al. 11C-methionine PET/CT in 99mTc-sestamibi-negative hyperparathyroidism in patients with renal failure on chronic haemodialysis. European Journal of Nuclear Medicine and Molecular Imaging. 2006;33:453-59.

(50)   Shane E. Parathyroid Carcinoma. Journal of Clinical Endocrinology & Metabolism. 2001;86:485-93.

(51)   Herrmann K, Takei T, Kanegae K, Shiga T, Buck A, Altomonte J et al. Clinical Value and Limitations of [11C]-Methionine PET for Detection and Localization of Suspected Parathyroid Adenomas. Molecular Imaging and Biology. 2009;11:356-63.

(52)   Weber T, Cammerer G, Schick C, Solbach C, Hillenbrand A, Barth TF et al. C-11 Methionine Positron Emission Tomography/Computed Tomography Localizes Parathyroid Adenomas in Primary Hyperparathyroidism. Horm Metab Res. 2010;42:209,214.

(53)   Cheung K, Wang T, Farrokhyar F, Roman S, Sosa J. A Meta-analysis of Preoperative Localization Techniques for Patients with Primary Hyperparathyroidism. Annals of Surgical Oncology.1-7.

(54)   Harrison B, Triponez F. Intraoperative adjuncts in surgery for primary hyperparathyroidism. Langenbeck’s Archives of Surgery. 2009;394:799-809.

(55)   Adler JT, Chen H, Schaefer S, Sippel RS. Does Routine Use of Ultrasound Result in Additional Thyroid Procedures in Patients with Primary Hyperparathyroidism? Journal of the American College of Surgeons. 2010;211:536-39.

(56)   Christensen SE, Nissen PH, Vestergaard P, Mosekilde L. Familial hypocalciuric hypercalcaemia: a review. Curr Opin Endocrinol Diabetes Obes. 2011.

(57)   Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Rejnmark L, Brixen K et al. Skeletal consequences of familial hypocalciuric hypercalcaemia versus primary hyperparathyroidism. Clin Endocrinol (Oxf). 2009.

(58)   Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Brixen K, Mosekilde L. Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clinical Endocrinology. 2008;69:713-20.

(59)   Pidasheva S, D’Souza-Li L, Canaff L, Cole DEC, Hendy GN. CASRdb: calcium-sensing receptor locus-specific database for mutations causing familial (benign) hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum Mutat. 2004;24:107-11.

(60)   Nissen PH, Christensen SE, Wallace A, Heickendorff L, Brixen K, Mosekilde L. Multiplex ligation-dependent probe amplification (MLPA) screening for exon copy number variation in the calcium sensing receptor gene: no large rearrangements identified in patients with calcium metabolic disorders. Clinical Endocrinology. 2010;72:758-62.

(61)   Pallais JC, Kifor O, Chen YB, Slovik D, Brown EM. Acquired Hypocalciuric Hypercalcemia Due to Autoantibodies against the Calcium-Sensing Receptor. New England Journal of Medicine. 2004;351:362-69.

(62)   Pallais JC, Kemp EH, Bergwitz C, Kantham L, Slovik DM, Weetman AP et al. Autoimmune Hypocalciuric Hypercalcemia Unresponsive to Glucocorticoid Therapy in a Patient with Blocking Autoantibodies against the Calcium-Sensing Receptor. Journal of Clinical Endocrinology & Metabolism. 2011;96:672-80.

(63)   Rejnmark L, Vestergaard P, Pedersen AR, Heickendorff L, Andreasen F, Mosekilde L. Dose-effect relations of loop- and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded Latin-square multiple cross-over study in postmenopausal osteopenic women. Eur J Clin Invest. 2003;33:41-50.

(64)   Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Brixen K, Mosekilde L. Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clinical Endocrinology. 2008;69:713-20.

(65)   Broome J, Solorzano C. Lithium Use and Primary Hyperparathyroidism. Endocrine Practice. 2011;17:31-35.

(66)   Skandarajah A, Barlier A, Morlet-Barlat N, Sebag F, Enjalbert A, Conte-Devolx B et al. Should Routine Analysis of the MEN1 Gene be Performed in all Patients with Primary Hyperparathyroidism Under 40 Years of Age? World Journal of Surgery. 2010;34:1294-98.

(67)   Marsh DJ, Gimm O. Multiple endocrine neoplasia: types 1 and 2. Adv Otorhinolaryngol. 2011;70:84-90.

(68)   Åkerstrøm G, Stålberg P. Surgical Management of MEN-1 and -2: State of the Art. Surg Clin North Am. 2009;89:1047-68.

(69)   Chanson P, Cadiot G, Murat A. Management of patients and subjects at risk for multiple endocrine neoplasia type 1: MEN 1. GENEM 1. Groupe d’Etude des Neoplasies Endocriniennes Multiples de type 1. Horm Res. 1997;47:211-20.

(70)   Lim S, Elston MS, Gill AJ, Marsh DJ, Conaglen JV. Metastatic parathyroid carcinoma initially misdiagnosed as parathyroid adenoma: the role of parafibromin in increasing diagnostic accuracy. Internal Medicine Journal. 2011;41:695-99.

(71)   Bilezikian JP, Khan AA, Potts JT, Jr., on behalf of the Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop. Journal of Clinical Endocrinology Metabolism. 2009;94:335-39.

(72)   Udelsman R, Pasieka JL, Sturgeon C, Young JEM, Clark OH. Surgery for Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop. Journal of Clinical Endocrinology Metabolism. 2009;94:366-72.

(73)   Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop. Journal of Clinical Endocrinology Metabolism. 2009;94:351-65.

(74)   Ruda JM, Hollenbeak CS, Stack BC. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngology — Head and Neck Surgery. 2005;132:359-72.

(75)   Bergenfelz A, Jansson S, Mårtensson H, Reihnér E, Wallin G, Kristoffersson A et al. Scandinavian quality register for thyroid and parathyroid surgery: audit of surgery for primary hyperparathyroidism. Langenbeck’s Archives of Surgery. 2007;392:445-51.

(76)   Corsello SM, Paragliola RM, Locantore P, Ingraudo F, Ricciato MP, Rota CA et al. Post-surgery severe hypocalcemia in primary hyperparathyroidism preoperatively treated with zoledronic acid. Hormones (Athens ). 2010;9:338-42.

(77)   Lee IT, Sheu WH-H, Tu ST, Kuo SW, Pei D. Bisphosphonate pretreatment attenuates hungry bone syndrome postoperatively in subjects with primary hyperparathyroidism. Journal of Bone and Mineral Metabolism. 2006;24:255-58.

(78)   Davenport A, Stearns MP. Administration of pamidronate helps prevent immediate postparathyroidectomy hungry bone syndrome. Nephrology. 2007;12:386-90.

(79)   Fleisch HA. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med. 1997;29:55-62.

(80)   Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U et al. Comparison of Two Diets for the Prevention of Recurrent Stones in Idiopathic Hypercalciuria. N Engl J Med. 2002;346:77-84.

(81)   Locker FG, Silverberg SJ, Bilezikian JP. Optimal Dietary Calcium Intake in Primary Hyperparathyroidism. The American Journal of Medicine. 1997;102:543-50.

(82)   Silverberg SJ, Shane E, Dempster DW, Bilezikian JP. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med. 1999;107:561-67.

(83)   Rao DS, Honasoge M, Divine GW, Phillips ER, Lee MW, Ansari MR et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab. 2000;85:1054-58.

(84)   Ozbey N, Erbil Y, Ademoglu E, Ozarmagan S, Barbaros U, Bozbora A. Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism. World J Surg. 2006;30:321-26.

(85)   Beyer TD, Chen EL, Nilubol N, Prinz RA, Solorzano CC. Short-Term Outcomes of Parathyroidectomy in Patients With or Without 25-Hydroxy Vitamin D Insufficiency. Journal of Surgical Research. 2007;143:145-50.

(86)   Stein EM, Dempster DW, Udesky J, Zhou H, Bilezikian JP, Shane E et al. Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. Bone. 2011;48:557-61.

(87)   Stewart ZA, Blackford A, Somervell H, Friedman K, Garrett-Mayer E, Dackiw AP et al. 25-hydroxyvitamin D deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally invasive parathyroidectomy. Surgery. 2005;138:1018-25.

(88)   Untch BR, Barfield ME, Dar M, Dixit D, Leight J, Olson J. Impact of 25-Hydroxyvitamin D Deficiency on Perioperative Parathyroid Hormone Kinetics and Results in Patients with Primary Hyperparathyroidism. Surgery. 2007;142:1022-26.

(89)   Grubbs EG, Rafeeq S, Jimenez C, Feng L, Lee JE, Evans DB et al. Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial? Surgery. 2008;144:852-58.

(90)   Isidro M, Ruano Bn. Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency. Endocrine. 2009.

(91)   Mikhail N. Clinical significance of vitamin D deficiency in primary hyperparathyroidism, and safety of vitamin D therapy. South Med J. 2011;104:29-33.

(92)   Lew JI, Solorzano CC. Surgical Management of Primary Hyperparathyroidism: State of the Art. Surg Clin North Am. 2009;89:1205-25.

(93)   Hundley JC, Woodrum DT, Saunders BD, Doherty GM, Gauger PG. Revisiting lithium-associated hyperparathyroidism in the era of intraoperative parathyroid hormone monitoring. Surgery. 2005;138:1027-32.

(94)   Skandarajah A, Palazzo F, Henry JF. Lithium-Associated Hyperparathyroidism: Surgical Strategies in the Era of Minimally Invasive Parathyroidectomy. World Journal of Surgery. 2011;35:2432-39.

(95)   Christiansen P, Mollerup CL. Ny teknik ved behandling af primær hyperparatyroidisme. Ugeskr Laeger. 2005;167:918-24.

(96)   Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg. 2002;235:665-70.

(97)   Irvin GL, III, Carneiro DM, Solorzano CC. Progress in the operative management of sporadic primary hyperparathyroidism over 34 years. Ann Surg. 2004;239:704-8.

(98)   Beyer TD, Solorzano CC, Starr F, Nilubol N, Prinz RA. Parathyroidectomy outcomes according to operative approach. The American Journal of Surgery. 2007;193:368-73.

(99)   Bergenfelz A, Lindblom P, Tibblin S, Westerdahl J. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: a prospective randomized controlled trial. Ann Surg. 2002;236:543-51.

(100)   Bergenfelz A, Kanngiesser V, Zielke A, Nies C, Rothmund M. Conventional bilateral cervical exploration versus open minimally invasive parathyroidectomy under local anaesthesia for primary hyperparathyroidism. Br J Surg. 2005;92:190-197.

(101)   Russell CFJ, Dolan SJ, Laird JD. Randomized clinical trial comparing scan-directed unilateral versus bilateral cervical exploration for primary hyperparathyroidism due to solitary adenoma. Br J Surg. 2006;93:418-21.

(102)   Westerdahl J, Bergenfelz A. Unilateral versus bilateral neck exploration for primary hyperparathyroidism: five-year follow-up of a randomized controlled trial. Ann Surg. 2007;246:976-80.

(103)   Trolle W, Moller H, Bennedbaek FN, Nygaard B, Sorensen CH. Minimalt invasiv operation for hyperparathyroidisme. Ugeskr Laeger. 2010;172:33-38.

(104)   Kumar A, Kumar S, Aggarwal S, Kumar R, Tandon N. Thoracoscopy: the preferred method for excision of mediastinal parathyroids. Surg Laparosc Endosc Percutan Tech. 2002;12:295-300.

(105)   Harrison B. What steps should be considered in the patient who has had a negative cervical exploration for primary hyperparathyroidism? Clinical Endocrinology. 2009;71:624-27.

(106)   Hessman O, Westerdahl J, Al Suliman N, Christiansen P, Hellman P, Bergenfelz A. Randomized clinical trial comparing open with video-assisted minimally invasive parathyroid surgery for primary hyperparathyroidism. Br J Surg. 2010;97:177-84.

(107)   Gracie D, Hussain SSM. Use of minimally invasive parathyroidectomy techniques in sporadic primary hyperparathyroidism: systematic review. The Journal of Laryngology & Otology. 2011;1:1-7.

(108)   Rubello D, Mariani G, Pelizzo MR. Minimally invasive radio-guided parathyroidectomy on a group of 452 primary hyperparathyroid patients: refinement of preoperative imaging and intraoperative procedure. Nuklearmedizin. 2007;46:85-92.

(109)   Rubello D, Giannini S, De Carlo E, Mariani G, Muzzio PC, Rampin L et al. Minimally invasive (99m)Tc-sestamibi radioguided surgery of parathyroid adenomas. Panminerva Med. 2005;47:99-107.

(110)   Han N, Bumpous JM, Goldstein RE, Fleming MM, Flynn MB. Intra-Operative Parathyroid Identification Using Methylene Blue in Parathyroid Surgery. The American surgeon. 2007;73:820-823.

(111)   Licker M, Diaper J, Robert J, Ellenberger C. Effects of methylene blue on propofol requirement during anaesthesia induction and surgery. Anaesthesia. 2008;63:352-57.

(112)   Bergenfelz A, Hellman P, Harrison B, Sitges-Serra A, Dralle H. Positional statement of the European Society of Endocrine Surgeons (ESES) on modern techniques in pHPT surgery. Langenbeck’s Archives of Surgery. 2009;394:761-64.

(113)   Carling T, Donovan P, Rinder C, Udelsman R. Minimally Invasive Parathyroidectomy Using Cervical Block: Reasons for Conversion to General Anesthesia. Arch Surg. 2006;141:401-4.

(114)   Allendorf J, DiGorgi M, Spanknebel K, Inabnet W, Chabot J, LoGerfo P. 1112 Consecutive Bilateral Neck Explorations for Primary Hyperparathyroidism. World Journal of Surgery. 2007;31:2075-80.

(115)   Cheong YT, Taib NA, Normayah K, Hisham AN. Total Parathyroidectomy Under Local Anaesthesia for Renal Hyperparathyroidism. Asian Journal of Surgery. 2009;32:51-54.

(116)   Chau JK, Hoy M, Tsui B, Harris JR. Minimally invasive parathyroidectomy under local anesthesia: patient satisfaction and overall outcome. J Otolaryngol Head Neck Surg. 2010;39:361-69.

(117)   Clerici T, Kull C, Sege D, Rittmann WW. [Incidence of recurrence in long-term follow-up of 100 patients after surgery for primary hyperparathyroidism]. Helv Chir Acta. 1992;58:767-70.

(118)   Amstrup AK, Rejnmark L, Vestergaard P, Sikjaer T, Rolighed L, Heickendorff L et al. Vitamin D status, physical performance and body mass in patients surgically cured for primary hyperparathyroidism compared with healthy controls – a cross-sectional study. Clin Endocrinol (Oxf). 2011;74:130-136.

(119)   Sarfati E, Billotey C, Halimi B, Fritsch S, Cattan P, Dubost C. Early localization and reoperation for persistent primary hyperparathyroidism. Br J Surg. 1997;84:98-100.

(120)   Hessman O, Stålberg P, Sundin A, Garske U, Rudberg C, Eriksson LG et al. High Success Rate of Parathyroid Reoperation may be Achieved with Improved Localization Diagnosis. World Journal of Surgery. 2008;32:774-81.

(121)   Henry JF. Reoperation for primary hyperparathyroidism: tips and tricks. Langenbecks Arch Surg. 2010;395:103-9.

(122)   Wells SA, Jr., Debenedetti MK, Doherty GM. Recurrent or persistent hyperparathyroidism. J Bone Miner Res. 2002;17 Suppl 2:N158-N162.

(123)   Hubbard J, Sebag Fdr, Maweja S, Henry JF. Primary hyperparathyroidism in MEN 1 – how radical should surgery be? Langenbeck’s Archives of Surgery. 2002;386:553-57.

(124)   Goudet P, Cougard P, Verges B, Murat A, Carnaille B, Calender A et al. Hyperparathyroidism in multiple endocrine neoplasia type I: surgical trends and results of a 256-patient series from Groupe D’etude des Neoplasies Endocriniennes Multiples Study Group. World J Surg. 2001;25:886-90.

(125)   Hellman P, Skogseid B, Oberg K, Juhlin C, Akerstrom G, Rastad J. Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1. Surgery. 1998;124:993-99.

(126)   Frank-Raue K, Raue F. Multiple endocrine neoplasia type 2 (MEN 2). European Journal of Cancer. 2009;45, Supplement 1:267-73.

(127)   Tonelli F, Marcucci T, Giudici F, Falchetti A, Brandi ML. Surgical Approach in Hereditary Hyperparathyroidism. Endocrine Journal. 2009;56:827-41.

(128)   Åkerstrøm G. Symposium on Evidence-Based Endocrine Surgery (3: Hyperparathyroidism). World Journal of Surgery. 2009;33:2219-23.

(129)   Saunders B, Saunders E, Gauger P. Lithium Therapy and Hyperparathyroidism: An Evidence-Based Assessment. World Journal of Surgery. 2009;33:2314-23.

(130)   Pitt SC, Panneerselvan R, Sippel RS, Chen H. Influence of morbid obesity on parathyroidectomy outcomes in primary hyperparathyroidism. The American Journal of Surgery. 2010;199:410-415.

(131)   Norman J, Aronson K. Outpatient parathyroid surgery and the differences seen in the morbidly obese. Otolaryngology — Head and Neck Surgery. 2007;136:282-86.

(132)   Schnatz PF, Curry SL. Primary hyperparathyroidism in pregnancy: evidence-based management. Obstet Gynecol Surv. 2002;57:365-76.

(133)   Kohlmeier L, Marcus R. Calcium disorders of pregnancy. Endocrinol Metab Clin North Am. 1995;24:15-39.

(134)   Hultin H, Hellman P, Lundgren E, Olovsson M, Ekbom A, Rastad J et al. Association of Parathyroid Adenoma and Pregnancy with Preeclampsia. Journal of Clinical Endocrinology & Metabolism. 2009;94:3394-99.

(135)   Norman J, Politz D, Politz L. Hyperparathyroidism during pregnancy and the effect of rising calcium on pregnancy loss: a call for earlier intervention. Clin Endocrinol (Oxf). 2009;71:104-9.

(136)   Ficinski ML, Mestman JH. Primary hyperparathyroidism during pregnancy. Endocr Pract. 1996;2:362-67.

(137)   Montoro MN, Collea JV, Mestman JH. Management of hyperparathyroidism in pregnancy with oral phosphate therapy. Obstet Gynecol. 1980;55:431-34.

(138)   Nilsson IL, Adner N, Reihnér E, Palme-Kilander C, Edstrom G, Degerblad M. Primary Hyperparathyroidism in Pregnancy: A Diagnostic and Therapeutic Challenge. Journal of Women’s Health. 2010;19:1117-21.

(139)   Kollars J, Zarroug AE, van Heerden J, Lteif A, Stavlo P, Suarez L et al. Primary Hyperparathyroidism in Pediatric Patients. Pediatrics. 2005;115:974-80.

(140)   Loh KC, Duh QY, Shoback D, Gee L, Siperstein A, Clark OH. Clinical profile of primary hyperparathyroidism in adolescents and young adults. Clinical Endocrinology. 1998;48:435-43.

(141)   Rapaport D, Ziv Y, Rubin M, Huminer D, Dintsman M. Primary hyperparathyroidism in children. J Pediatr Surg. 1986;21:395-97.

(142)   Cupisti K, Raffel A, Dotzenrath C, Krausch M, R+Âher HD, Schulte KM. Primary Hyperparathyroidism in the Young Age Group: Particularities of Diagnostic and Therapeutic Schemes. World Journal of Surgery. 2004;28:1153-56.

(143)   Vanstone MB, Udelsman RD, Cheng DW, Carpenter TO. Rapid Correction of Bone Mass after Parathyroidectomy in an Adolescent with Primary Hyperparathyroidism. Journal of Clinical Endocrinology & Metabolism. 2011;96:E347-E350.

(144)   Kebebew E, Duh QY, Clark OH. Parathyroidectomy for Primary Hyperparathyroidism in Octogenarians and Nonagenarians: A Plea for Early Surgical Referral. Arch Surg. 2003;138:867-71.

(145)   Chen H, Parkerson S, Udelsman R. Parathyroidectomy in the Elderly: Do the Benefits Outweigh the Risks? World Journal of Surgery. 1998;22:531-36.

(146)   Chigot JP, Menegaux F, Achrafi H. Should primary hyperparathyroidism be treated surgically in elderly patients older than 75 years? Surgery. 1995;117:397-401.

(147)   Udén P, Chan A, Duh QY, Siperstein A, Clark OH. Primary hyperparathyroidism in younger and older patients: Symptoms and outcome of surgery. World Journal of Surgery. 1992;16:791-97.

(148)   Wu B, Haigh PI, Hwang R, Ituarte PHG, Liu ILA, Hahn TJ et al. Underutilization of Parathyroidectomy in Elderly Patients with Primary Hyperparathyroidism. Journal of Clinical Endocrinology Metabolism. 2010;95:4324-30.

(149)   Politz D, Norman J. Hyperparathyroidism in Patients Over 80: Clinical Characteristics and Their Ability to Undergo Outpatient Parathyroidectomy. Thyroid. 2007;17:333-39.

(150)   Thomas DC, Roman SA, Sosa JA. Parathyroidectomy in the Elderly: Analysis of 7313 Patients. Journal of Surgical Research. 2011;170:240-246.

(151)   Carty SE, Roberts MM, Virji MA, Haywood L, Yim JH. Elevated serum parathormone level after “concise parathyroidectomy” for primary sporadic hyperparathyroidism. Surgery. 2002;132:1086-93.

(152)   Jarhult J, Nordenstrom J, Perbeck L. Reoperation for suspected primary hyperparathyroidism. Br J Surg. 1993;80:453-56.

(153)   Yarbrough DE, Thompson GB, Kasperbauer JL, Harper CM, Grant CS. Intraoperative electromyographic monitoring of the recurrent laryngeal nerve in reoperative thyroid and parathyroid surgery. Surgery. 2004;136:1107-15.

(154)   Nordenstrøm E, Westerdahl J, Isaksson A, Lindblom P, Bergenfelz A. Patients with Elevated Serum Parathyroid Hormone Levels after Parathyroidectomy: Showing Signs of Decreased Peripheral Parathyroid Hormone Sensitivity. World Journal of Surgery. 2003;27:212-15.

(155)   Brasier AR, Nussbaum SR. Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med. 1988;84:654-60.

(156)   Biskobing D. Significance of Elevated Parathyroid Hormone After Parathyroidectomy. Endocrine Practice. 2010;16:112-17.

(157)   Oltmann S, Maalouf N, Holt S. Significance of Elevated Parathyroid Hormone after Parathyroidectomy for Primary Hyperparathyroidism. Endocrine Practice. 2011;17:57-62.

(158)   Mandal AK, Udelsman R. Secondary hyperparathyroidism is an expected consequence of parathyroidectomy for primary hyperparathyroidism: a prospective study. Surgery. 1998;124:1021-26.

(159)   Mittendorf EA, McHenry CR. Persistent parathyroid hormone elevation following curative parathyroidectomy for primary hyperparathyroidism. Arch Otolaryngol Head Neck Surg. 2002;128:275-79.

(160)   Beyer TD, Solorzano CC, Prinz RA, Babu A, Nilubol N, Patel S. Oral vitamin D supplementation reduces the incidence of eucalcemic PTH elevation after surgery for primary hyperparathyroidism. Surgery. 2007;141:777-83.

(161)   Vestergaard H, Kristensen L. Normocalcemia and persistent elevated serum concentrations of 1GÇô84 parathyroid hormone after operation for sporadic parathyroid adenoma: evidence of increased morbidity from cardiovascular disease. World Journal of Surgery. 2002;26:657-60.

(162)   Bergenfelz A, Valdemarsson S, Tibblin S. Persistent elevated serum levels of intact parathyroid hormone after operation for sporadic parathyroid adenoma: evidence of detrimental effects of severe parathyroid disease. Surgery. 1996;119:624-33.

(163)   Stewart ZA, Blackford A, Somervell H, Friedman K, Garrett-Mayer E, Dackiw APB et al. 25-hydroxyvitamin D deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally invasive parathyroidectomy. Surgery. 2005;138:1018-26.

(164)   Sundhedsstyrelsen. Forebyggelse, diagnostik og behandling af D-vitaminmangel. København: Sundhedsstyrelsen; 2010.

(165)   Bergenfelz A, Valdermarsson S, Ahren B. Functional recovery of the parathyroid glands after surgery for primary hyperparathyroidism. Surgery. 1994;116:827-36.

(166)   Brasier AR, Wang CA, Nussbaum SR. Recovery of Parathyroid Hormone Secretion After Parathyroid Adenomectomy. Journal of Clinical Endocrinology & Metabolism. 1988;66:495-500.

(167)   Mittendorf EA, Merlino JI, McHenry CR. Post-parathyroidectomy hypocalcemia: incidence, risk factors, and management. Am Surg. 2004;70:114-19.

(168)   Westerdahl J, Lindblom P, Valdemarsson S, Tibblin S, Bergenfelz A. Risk factors for postoperative hypocalcemia after surgery for primary hyperparathyroidism. Arch Surg. 2000;135:142-47.

(169)   Vasher M, Goodman A, Politz D, Norman J. Postoperative Calcium Requirements in 6,000 Patients Undergoing Outpatient Parathyroidectomy: Easily Avoiding Symptomatic Hypocalcemia. Journal of the American College of Surgeons. 2010;211:49-54.

(170)   Dolan JP, Norton JA. Surgery for Persistent and Recurrent Primary Hyperparathyroidism. In: Doherty GM, Skögseid B, eds. Surgical Endocrinology. First ed. Philadelphia: Lippincott Williams & Wilkins; 2001: 173-87.

(171)   Mosekilde L. Primary hyperparathyroidism and the skeleton. Clin Endocrinol (Oxf). 2008;69:1-19.

(172)   Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 2000;321:598-602.

(173)   Hermann AP, Thomsen J, Vestergaard P, Mosekilde L, Charles P. Assessment of calcium intake. A quick method comparerd to a 7 days food diary. Calcif Tissue Int. 1999;64 (suppl 1):S82.

(174)   Harman CR, Grant CS, Hay ID, Hurley DL, van Heerden JA, Thompson GB et al. Indications, technique, and efficacy of alcohol injection of enlarged parathyroid glands in patients with primary hyperparathyroidism. Surgery. 1998;124:1011-19.

(175)   Stratigis S, Stylianou K, Mamalaki E, Perakis K, Vardaki E, Tzenakis N et al. Percutaneous ethanol injection therapy: a surgery-sparing treatment for primary hyperparathyroidism. Clinical Endocrinology. 2008;69:542-48.

(176)   Karstrup S, Hegedus L, Holm HH. Ultrasonically guided chemical parathyroidectomy in patients with primary hyperparathyroidism: a follow-up study. Clin Endocrinol (Oxf). 1993;38:523-30.

(177)   Mauz PS, Stiegler M, Holderried M, Brosch S. Complications of ultrasound guided percutaneous ethanol injection therapy of the thyroid and parathyroid glands. Ultraschall Med. 2005;26:142-45.

(178)   Bennedbak FN, Karstrup S, Hegedus L. Ultrasound guided laser ablation of a parathyroid adenoma. Br J Radiol. 2001;74:905-7.

(179)   Kovatcheva RD, Vlahov JD, Shinkov AD, Borissova AM, Hwang JH, Arnaud F et al. High-Intensity Focused Ultrasound to Treat Primary Hyperparathyroidism: A Feasibility Study in Four Patients. Am J Roentgenol. 2010;195:830-835.

(180)   Palmer M, Jakobsson S, Akerstrom G, Ljunghall S. Prevalence of hypercalcaemia in a health survey: a 14-year follow-up study of serum calcium values. Eur J Clin Invest. 1988;18:39-46.

(181)   Palmér M, Bergström R, Åkerstrøm G, Adami HO, Jakobsson S, Ljunghall S. Survival and renal function in untreated hypercalcaemia: Population-based Cohort Study with 14 Years of Follow-up. The Lancet. 1987;329:59-62.

(182)   Bollerslev J, Jansson S, Mollerup CL, Nordenstrom J, Lundgren E, Torring O et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab. 2007;92:1687-92.

(183)   Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti C, Viccica G et al. Surgery or Surveillance for Mild Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Clinical Trial. Journal of Clinical Endocrinology & Metabolism. 2007;92:3114-21.

(184)   Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized Controlled Clinical Trial of Surgery Versus No Surgery in Patients with Mild Asymptomatic Primary Hyperparathyroidism. Journal of Clinical Endocrinology Metabolism. 2004;89:5415-22.

(185)   Sankaran S, Gamble G, Bolland M, Reid IR, Grey A. Skeletal Effects of Interventions in Mild Primary Hyperparathyroidism: A Meta-Analysis. Journal of Clinical Endocrinology & Metabolism. 2010;95:1653-62.

(186)   Khan A, Grey A, Shoback D. Medical Management of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop. Journal of Clinical Endocrinology Metabolism. 2009;94:373-81.

(187)   Pyram R, Mahajan G, Gliwa A. Primary hyperparathyroidism: Skeletal and non-skeletal effects, diagnosis and management. Maturitas. 2011;70:246-55.

(188)   Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-41.

(189)   Khan AA, Bilezikian JP, Kung A, Syed ZA, Dubois SJ, Standish TI. Alendronate in Men with Primary Hyperparathyroidism. Endocr Pract. 2009;1-19.

(190)   Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:3319-25.

(191)   Vestergaard P. Current pharmacological options for the management of primary hyperparathyroidism. Drugs. 2006;66:2189-211.

(192)   Norman J, Lopez J, Politz D. Cinacalcet (Sensipar) Provides no Measurable Clinical Benefits for Patients with Primary Hyperparathyroidism and may Accelerate Bone Loss with Prolonged Use. Annals of Surgical Oncology. 2011;1-6.

(193)   Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M. The Calcimimetic Cinacalcet Normalizes Serum Calcium in Subjects with Primary Hyperparathyroidism. Journal of Clinical Endocrinology & Metabolism. 2003;88:5644-49.

(194)   Vestergaard P, Nielsen LR, Mosekilde L. Cinacalcet – et nyt medicinsk behandlingsprincip til sekundær hyperparatyroidisme ved uræmi, parathyroideacancer og primær hyperparatyroidisme. Ugeskr Laeger. 2006;168:29-32.

(195)   Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet Hydrochloride Maintains Long-Term Normocalcemia in Patients with Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2005;90:135-41.

(196)   Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S et al. Cinacalcet Treatment of Primary Hyperparathyroidism: Biochemical and Bone Densitometric Outcomes in a Five-Year Study. Journal of Clinical Endocrinology & Metabolism. 2009;94:4860-4867.

(197)   Carroll R, Matfin G. Review: Endocrine and metabolic emergencies: hypercalcaemia. Therapeutic Advances in Endocrinology and Metabolism. 2010;1:225-34.

(198)   Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC et al. Cinacalcet Hydrochloride Reduces the Serum Calcium Concentration in Inoperable Parathyroid Carcinoma. Journal of Clinical Endocrinology & Metabolism. 2007;92:3803-8.

(199)   Iglesias P, Diez JJ. Current treatments in the management of patients with primary hyperparathyroidism. Postgrad Med J. 2009;85:15-23.